Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report by Type, Country and Growth Forecast, 2022-2028

The Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market should witness market growth of 2.9% CAGR during the forecast period (2022-2028).

Dietary factors, medications that can decrease LES competence, and obesity all help to cause the reflux of too much acid into the esophagus, whose mucosa is unfamiliar with this aggressive element. In recent years, the loss of the esophageal mucosa's protective qualities has been suggested as another factor in the pathophysiology of GERD. Several investigations have shown that most individuals with GERD, especially those with non-erosive reflux disease (NERD), who do not have mucosal lesions during endoscopy, have poor mucosal resistance of the esophagus.

Moreover, due to a compromised mucosal barrier, the development of dilated intercellular spaces (DIS) is frequent in individuals with genuine NERD and reflux hypersensitivity (RH). On the other hand, microscopic esophagitis, including DIS, is substantially less common in controls (15%) and patients with functional heartburn (FH) (13%), compared to patients with RH (65%) and patients with excess acid (77%), in patients with NERD.

Australians aged 18 and older who were overweight or obese made up 2 out of 3 (67%) of the population in 2017-18 (36% were overweight but not obese, and 31% were obese). 12.5 million adults, roughly. In comparison to women, males were more likely to be overweight (75% vs. 60%) and more likely to be obese (33% vs. 30%). Obesity is more prevalent in older age groups; 16% of individuals between the ages of 18 and 24 and 41% of persons between the ages of 65 and 74 were obese. Women were more likely than males to have a waist circumference significantly related to an elevated risk of developing chronic illnesses (46% of women versus 36% of men). This will expedite the market's growth in the coming years.

The China market dominated the Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $441.5 Million by 2028. The Japan market is estimated to grow a CAGR of 2.3% during (2022-2028). Additionally, The India market would experience a CAGR of 3.6% during (2022-2028).

Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

By Type

• Antacids
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Blockers
• Pro-kinetic Agents

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• AstraZeneca PLC
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigus Ltd.
• Sebela Pharmaceuticals
• Phathom Pharmaceuticals, Inc.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free